047920.KQ
HLB제약
KOE · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 9,510.00
−4.42%Year over year
Reported trailing growth
- Revenue
- +68.6%
- EBITDA
- -38.4%
- EBIT
- +1132.1%
- EPS
- -52.2%
- Free cash flow
- +11.1%
- Operating cash flow
- +541.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +24.1%
- EBITDA
- -24.7%
- EBIT
- -27.8%
- Net income
- +126.3%
- EPS
- +120.4%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026